Non-Small Cell Lung Cancer (NSCLC) Drug Market in China 2021
The non-small cell lung cancer (NSCLC) drug market in China in terms of revenue is set to grow by US$ 13 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 17.1% during the forecast period, according to data and analytics company StrategyHelix.
The report provides up-to-date market size data for period 2017-2020 and forecast to 2027 covering key market aspects like sales value for non-small cell lung cancer (NSCLC) drug. The China non-small cell lung cancer (NSCLC) drug market is segmented on the basis of type, incidence of gene mutation. By type, it is categorized into adenocarcinoma, large cell carcinoma, sarcomatoid carcinoma, squamous-cell carcinoma, and others. By incidence of gene mutation, the non-small cell lung cancer (NSCLC) drug market is divided into ALK (anaplastic lymphoma kinase), EGFR (epidermal growth factor receptor), KRAS (Kirsten rat sarcoma viral oncogene homologue), and others.
The report has profiled some of the key players of the market such as AstraZeneca plc., Betta Pharmaceuticals Co. Ltd., Bristol-Myers Squibb Company, Merck & Co., Novartis International AG, Pfizer Inc., Roche Holding AG, Takeda Pharmaceutical Company.
The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the non-small cell lung cancer (NSCLC) drug market to help drive informed decision making for industry executives, policy makers, academic, and analysts.
Report Scope
Type: adenocarcinoma, large cell carcinoma, sarcomatoid carcinoma, squamous-cell carcinoma, and others
Incidence of gene mutation: ALK (anaplastic lymphoma kinase), EGFR (epidermal growth factor receptor), KRAS (Kirsten rat sarcoma viral oncogene homologue), and others
Years Considered: this report covers the period 2017 to 2027
Key Benefits for Stakeholders
Get a comprehensive picture of the China non-small cell lung cancer (NSCLC) drug market
Pinpoint growth sectors and trends for investment
Understand what the future of the non-small cell lung cancer (NSCLC) drug market in China looks like
Identify the competitive landscape and window of opportunity
The report provides up-to-date market size data for period 2017-2020 and forecast to 2027 covering key market aspects like sales value for non-small cell lung cancer (NSCLC) drug. The China non-small cell lung cancer (NSCLC) drug market is segmented on the basis of type, incidence of gene mutation. By type, it is categorized into adenocarcinoma, large cell carcinoma, sarcomatoid carcinoma, squamous-cell carcinoma, and others. By incidence of gene mutation, the non-small cell lung cancer (NSCLC) drug market is divided into ALK (anaplastic lymphoma kinase), EGFR (epidermal growth factor receptor), KRAS (Kirsten rat sarcoma viral oncogene homologue), and others.
The report has profiled some of the key players of the market such as AstraZeneca plc., Betta Pharmaceuticals Co. Ltd., Bristol-Myers Squibb Company, Merck & Co., Novartis International AG, Pfizer Inc., Roche Holding AG, Takeda Pharmaceutical Company.
The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the non-small cell lung cancer (NSCLC) drug market to help drive informed decision making for industry executives, policy makers, academic, and analysts.
Report Scope
Type: adenocarcinoma, large cell carcinoma, sarcomatoid carcinoma, squamous-cell carcinoma, and others
Incidence of gene mutation: ALK (anaplastic lymphoma kinase), EGFR (epidermal growth factor receptor), KRAS (Kirsten rat sarcoma viral oncogene homologue), and others
Years Considered: this report covers the period 2017 to 2027
Key Benefits for Stakeholders
Get a comprehensive picture of the China non-small cell lung cancer (NSCLC) drug market
Pinpoint growth sectors and trends for investment
Understand what the future of the non-small cell lung cancer (NSCLC) drug market in China looks like
Identify the competitive landscape and window of opportunity
1. MARKET DEFINITION
2. RESEARCH METHODOLOGY
3. MARKET DATA & OUTLOOK
3.1 Market Value
3.2 Market Value Forecast
4. NON-SMALL CELL LUNG CANCER (NSCLC) DRUG MARKET BY TYPE
4.1 Adenocarcinoma
4.2 Large Cell Carcinoma
4.3 Sarcomatoid Carcinoma
4.4 Squamous-Cell Carcinoma
4.5 Others
5. NON-SMALL CELL LUNG CANCER (NSCLC) DRUG MARKET BY INCIDENCE OF GENE MUTATION
5.1 Alk (Anaplastic Lymphoma Kinase)
5.2 Egfr (Epidermal Growth Factor Receptor)
5.3 Kras (Kirsten Rat Sarcoma Viral Oncogene Homologue)
5.4 Others
6. COMPANY PROFILES
6.1 AstraZeneca plc.
6.2 Betta Pharmaceuticals Co., Ltd.
6.3 Bristol-Myers Squibb Company
6.4 Merck & Co.
6.5 Novartis International AG
6.6 Pfizer, Inc.
6.7 Roche Holding AG
6.8 Takeda Pharmaceutical Company
7. APPENDIX
7.1 About StrategyHelix
7.2 Disclaimer
2. RESEARCH METHODOLOGY
3. MARKET DATA & OUTLOOK
3.1 Market Value
3.2 Market Value Forecast
4. NON-SMALL CELL LUNG CANCER (NSCLC) DRUG MARKET BY TYPE
4.1 Adenocarcinoma
4.2 Large Cell Carcinoma
4.3 Sarcomatoid Carcinoma
4.4 Squamous-Cell Carcinoma
4.5 Others
5. NON-SMALL CELL LUNG CANCER (NSCLC) DRUG MARKET BY INCIDENCE OF GENE MUTATION
5.1 Alk (Anaplastic Lymphoma Kinase)
5.2 Egfr (Epidermal Growth Factor Receptor)
5.3 Kras (Kirsten Rat Sarcoma Viral Oncogene Homologue)
5.4 Others
6. COMPANY PROFILES
6.1 AstraZeneca plc.
6.2 Betta Pharmaceuticals Co., Ltd.
6.3 Bristol-Myers Squibb Company
6.4 Merck & Co.
6.5 Novartis International AG
6.6 Pfizer, Inc.
6.7 Roche Holding AG
6.8 Takeda Pharmaceutical Company
7. APPENDIX
7.1 About StrategyHelix
7.2 Disclaimer
